[細胞・遺伝子治療] Lonzaが Gamida Cell とOmidubicel の商用生産における受託製造開発契約を締結

・Strategic manufacturing agreement is signed for the future commercial production of omidubicel, a Phase 3 investigational advanced cell therapy designed to enhance the life-saving benefits of hematopoietic stem cell (bone marrow) transplant

・The agreement follows a successful multi-year clinical manufacturing relationship and provides Gamida Cell with a path to commercial supply of omidubicel

・Under this multi-year agreement, Lonza will construct and dedicate production suites for anticipated commercial launch
（リンク先より全文をご覧いただけます/英語）

• リリース元を見る